<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716404</url>
  </required_header>
  <id_info>
    <org_study_id>CL0015</org_study_id>
    <nct_id>NCT00716404</nct_id>
  </id_info>
  <brief_title>Post-Market Observational Study of Intra-Renal Drug Delivery</brief_title>
  <acronym>PROVIDE</acronym>
  <official_title>Post-Market Observational Study of Intra-Renal Drug Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FlowMedica, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FlowMedica, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational, multi-center study with consecutive enrollment. Up to
      1,000 patients will be enrolled. The objective of this post-marketing surveillance study is
      to collect clinical usage patterns of the Benephit Infusion Systems. As a result, FlowMedica
      will be able to:

        1. Better understand and quantify usage patterns including patient characteristics,
           adjunctive procedures, and infusion agents.

        2. Collect user-interface information and overall customer satisfaction.

        3. Monitor post-marketing device performance.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    FlowMedica was purchased by AngioDynamics. Study will be re-started by AngioDynamics.
  </why_stopped>
  <start_date>April 2008</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Targeted Renal Therapy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>All (consecutive) patients in whom one or more components of the Benephit Infusion System are planned to be used are eligible for enrollment in the study and should be offered informed consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Targeted Renal Therapy</intervention_name>
    <description>Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Benephit CV Infusion System</other_name>
    <other_name>Benephit PV Infusion System</other_name>
    <other_name>Benephit PVMini Infusion System</other_name>
    <other_name>Benephit PVSolo Infusion System</other_name>
    <other_name>Benephit XT Infusion System</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients in whom one or more components of the Benephit Infusion System are
        planned to be used.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Exposure to one or more components of the Benephit Infusion System

          -  Ability to give written informed consent

        Exclusion Criteria:

          -  Inclusion in another clinical study that may affect usage of the Benephit system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A Tumlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southeast Renal Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David E Allie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute of the South</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Owensboro Heart &amp; Vascular</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Heart &amp; Vascular</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.flowmedica.com</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2008</study_first_submitted>
  <study_first_submitted_qc>July 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Burt Goodson/Director, Scientific Affairs</name_title>
    <organization>AngioDynamics, Inc.</organization>
  </responsible_party>
  <keyword>FlowMedica</keyword>
  <keyword>Benephit</keyword>
  <keyword>TRT</keyword>
  <keyword>Patients</keyword>
  <keyword>Components</keyword>
  <keyword>Benephit Infusion System</keyword>
  <keyword>Planned</keyword>
  <keyword>To be used</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

